Inhibikase Therapeutics (IKT) vs Lineage Cell Therapeutics (LCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Inhibikase Therapeutics is the larger company by market cap ($270.7 million vs $239.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | IKT | LCTX |
|---|---|---|
| Share price | $1.94 | $0.9476 |
| Market cap | $270.70M | $239.66M |
| 1-day change | -2.02% | +1.03% |
| YTD return | — | -43.26% |
| 1-year return | — | -45.23% |
| 5-year return | — | -59.68% |
| EPS (TTM) | $-0.43 | $-0.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.61 | $2.09 |
| 52-week low | $1.33 | $0.88 |
| Distance from 52-week high | -25.67% | -54.66% |
| Average volume | 665.95K | 1.15M |
| Shares outstanding | 139.54M | 252.91M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
IKT vs LCTX FAQ
Which is bigger, Inhibikase Therapeutics or Lineage Cell Therapeutics?
Inhibikase Therapeutics (IKT) is larger, with a market capitalization of $270.70M compared with $239.66M for Lineage Cell Therapeutics (LCTX).
Are Inhibikase Therapeutics and Lineage Cell Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.